PREVENTION OF OPPORTUNISTIC INFECTIONS IN IMMUNE-COMPROMISED SUBJECTS

• US 20100260720A1
• Filed: 12/05/2008
• Published: 10/14/2010
• Est. Priority Date: 12/17/2007
• Status: Active Grant

• Current Assignee: Societe des Produits Nestle SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Sprenger, Norbert
• Granted Patent: US 9,217,133 B2
• Time in Patent Office: Days
• US Class Current: 424/93.400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor

Abstract

This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.

Claims

1. A composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic selected from the group consisting of Bifidobacterium lactic, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group consisting of 2′

-fucosyllactose, 3′

fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose.

2. A composition according to claim 1 wherein the fucosylated oligosaccharide is 2′

-fucosyllactose.

3. A composition according to claim 1 wherein the probiotic is selected from the group consisting of Bifidobacterium lactis CNCM I-3446 and Bifidobacterium longum ATCC BAA-999.

4. A composition according to claim 1 which is an infant formula.

5. A composition according to claim 4 which comprises from 0.1 to 3 g fucosylated oligosaccharide/100 g composition.

6. A composition according to claim 4 which comprises from 10e3 to 10e12 cfu of the probiotic/g infant formula.

7. A composition according to claim 4 which comprises from 10e6 to 10e9 cfu of the probiotic/g infant formula.

8. A composition according to claim 4 which comprises at least one prebiotic in an amount of from 0.3 to 10% by weight of the composition.

9. A composition according to claim 1 which is a supplement and which comprises from 0.1 to 3 g fucosylated oligosaccharide and from 10e5 to 10e12 cfu of the probiotic per unit dose.

10. (canceled)

13. A method for the prevention of opportunistic infections in immune-compromised individuals comprising administering to the individual a composition comprising a probiotic selected from the group consisting of Bifidobacterium lactic, Bifidobacterium infantis, Bifidobacterium breve and Bifidobacterium longum and a fucosylated oligosaccharide selected from the group consisting of 2′

-fucosyllactose, 3′

fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose.

11. The method of claim 13 wherein the opportunistic infection is an infection caused by Pseudomonas aeruginosa.

12. The method of claim 13 wherein the infection caused by Pseudomonas aeruginosa is an infection of the respiratory, urinary or gastrointestinal tract.

14. A method according to claim 13 wherein the fucosylated oligosaccharide is 2′

-fucosyllactose.

15. A method according to claim 13 wherein the probiotic is selected from the group consisting of Bifidobacterium lactic CNCM I-3446 and Bifidobacterium longum ATCC BAA-999.

16. A method according to claim 13 wherein the composition is an infant formula.

17. A method according to claim 16 which comprises from 0.1 to 3 g fucosylated oligosaccharide/100 g composition.

18. A method according to claim 16 which comprises from 10e3 to 10e12 cfu of the probiotic/g infant formula.

19. A method according to claim 16 which comprises from 10e6 to 10e9 cfu of the probiotic/g infant formula.

20. A method according to claim 16 which comprises at least one prebiotic in an amount of from 0.3 to 10% by weight of the composition.

21. A method according to claim 13 wherein the composition is a supplement and which comprises from 0.1 to 3 g fucosylated oligosaccharide and from 10e5 to 10e12 cfu of the probiotic per unit dose.